Skip to main content
. 2020 Sep;374(3):438–451. doi: 10.1124/jpet.120.265868

Fig. 1.

Fig. 1.

Clinical utility of abiraterone and D4A in prostate cancer. (A) Endogenous androgen biosynthesis pathway showing the inhibitory effects of abiraterone/D4A on CYP17A1. (B) Schematic describing the two proposed mechanisms of slow-, tight-binding inhibition of CYP17A1 by abiraterone/D4A (C) Chemical structures of abiraterone and D4A in which the latter is formed via metabolism of abiraterone by 3β-hydroxysteroid dehydrogenase (3βHSD).